All News

Drops in flu vaccine coverage this season have been recorded among young children and pregnant people and racial/ethnic gaps in uptake continue, says CDC.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Tara Carr, MD, led a post hoc analysis of the NAVIGATOR phase 3 trial and presented data on tezepelumab efficacy in the vulnerable subgroup at the AAAAI 2022 meeting.

What questions might patients have about the CDC's new framework to measure COVID-19 community levels? Prep with our new slideshow.

Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.

Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Approximately 70% of Americans live in areas deemed low or medium risk for severe COVID-19 and can go maskless, according to new formula used by CDC.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

When choosing a migraine treatment for acute attack relief, the American Headache Society suggests following these steps.

Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

AAAAI 2022: Mepolizumab found effective in standard clinical care regardless of type 2 eosinophil biomarker status in patients with severe asthma.

Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.

AAAAI late-breaking science and findings that could change your treatment plan for patients with severe asthma, summarized by our editors for easy access.

AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Patients with asthma who did require hospitalization for SARS-CoV-2 infection were at greater risk for intubation and remdesivir treatment, a new study reports.